AU2007302715B2 - Probiotics for use in reducing the incidence and duration of illness - Google Patents

Probiotics for use in reducing the incidence and duration of illness Download PDF

Info

Publication number
AU2007302715B2
AU2007302715B2 AU2007302715A AU2007302715A AU2007302715B2 AU 2007302715 B2 AU2007302715 B2 AU 2007302715B2 AU 2007302715 A AU2007302715 A AU 2007302715A AU 2007302715 A AU2007302715 A AU 2007302715A AU 2007302715 B2 AU2007302715 B2 AU 2007302715B2
Authority
AU
Australia
Prior art keywords
child
symptoms
culture
respiratory disease
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007302715A
Other languages
English (en)
Other versions
AU2007302715A1 (en
Inventor
Gregory Leyer
Arthur Ouwehand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International N&H Denmark ApS
Original Assignee
International N&H Denmark ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007302715(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by International N&H Denmark ApS filed Critical International N&H Denmark ApS
Publication of AU2007302715A1 publication Critical patent/AU2007302715A1/en
Assigned to DUPONT NUTRITION BIOSCIENCES APS reassignment DUPONT NUTRITION BIOSCIENCES APS Amend patent request/document other than specification (104) Assignors: DANISCO A/S
Application granted granted Critical
Publication of AU2007302715B2 publication Critical patent/AU2007302715B2/en
Priority to AU2013201783A priority Critical patent/AU2013201783B2/en
Assigned to DUPONT NUTRITION BIOSCIENCES APS reassignment DUPONT NUTRITION BIOSCIENCES APS Request to Amend Deed and Register Assignors: DUPONT NUTRITION BIOSCIENCES APS
Assigned to INTERNATIONAL N&H DENMARK APS reassignment INTERNATIONAL N&H DENMARK APS Request to Amend Deed and Register Assignors: DUPONT NUTRITION BIOSCIENCES APS
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2007302715A 2006-10-02 2007-09-14 Probiotics for use in reducing the incidence and duration of illness Active AU2007302715B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013201783A AU2013201783B2 (en) 2006-10-02 2013-03-21 Probiotics for use in reducing the incidence and duration of illness

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84866206P 2006-10-02 2006-10-02
US60/848,662 2006-10-02
PCT/US2007/020033 WO2008042101A2 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing the incidence and duration of illness

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013201783A Division AU2013201783B2 (en) 2006-10-02 2013-03-21 Probiotics for use in reducing the incidence and duration of illness

Publications (2)

Publication Number Publication Date
AU2007302715A1 AU2007302715A1 (en) 2008-04-10
AU2007302715B2 true AU2007302715B2 (en) 2013-01-31

Family

ID=39268947

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007302715A Active AU2007302715B2 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing the incidence and duration of illness

Country Status (13)

Country Link
US (5) US20100040579A1 (enExample)
EP (2) EP2839836B2 (enExample)
JP (3) JP5896589B2 (enExample)
KR (2) KR101474188B1 (enExample)
CN (1) CN101528244B (enExample)
AU (1) AU2007302715B2 (enExample)
BR (1) BRPI0719787A2 (enExample)
DK (2) DK2068899T3 (enExample)
ES (2) ES2650375T5 (enExample)
FI (1) FI2839836T4 (enExample)
MX (1) MX2009003260A (enExample)
PL (2) PL2068899T3 (enExample)
WO (1) WO2008042101A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2835860B1 (en) 2009-12-02 2018-03-07 KMW Inc. Device selection structure
JP5885287B2 (ja) * 2010-09-02 2016-03-15 アサヒカルピスウェルネス株式会社 インフルエンザの予防および／または治療剤
CN103220921B (zh) * 2010-10-15 2015-12-16 科.汉森有限公司 免疫佐剂
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2455093A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
ES2856013T3 (es) 2013-11-15 2021-09-27 Nestle Sa Composiciones para su uso en la prevención o tratamiento de infecciones del TRS en bebés o niños jóvenes en riesgo
CN103798392B (zh) * 2014-03-07 2015-12-30 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
MX380540B (es) 2015-03-05 2025-03-12 Soc Des Produits Nestle S A Star Composiciones para uso en la prevención o el tratamiento de otitis o bronquitis en infantes o niños pequeños.
WO2020170982A1 (ja) 2019-02-21 2020-08-27 オリンパス株式会社 フローラ治療用留置体、フローラ治療法
WO2021062250A1 (en) 2019-09-25 2021-04-01 Tall Goods, Llc Methods for producing probiotics fortified avian eggs and egg products and formulations thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607905B1 (en) * 1996-11-29 2003-08-19 Bio-K + International Inc. Lactic ferment comprising a particular strain of lactobacillus acidophilus and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007A (en) * 1845-04-22 Improvement in separating tannin and coloring-matter in quercitron-bark
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
OA13142A (en) 2002-10-11 2006-12-13 Wyeth Corp Nutritional formulations containing synbiotic substances.
US20090257993A1 (en) * 2003-12-17 2009-10-15 M Rabet Laura Lactic Acid Producing Bacteria and Lung Function
DE102004026706A1 (de) * 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
WO2006088923A2 (en) * 2005-02-15 2006-08-24 Gorbach Sherwood L A food containing a probiotic and an isolated beta-glucan and methods of use thereof
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
KR101300086B1 (ko) 2005-10-06 2013-08-30 프로비 아베 자가면역질환의 치료를 위한 락토바실러스의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607905B1 (en) * 1996-11-29 2003-08-19 Bio-K + International Inc. Lactic ferment comprising a particular strain of lactobacillus acidophilus and use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENGMARK, S., et al., NUTRICION HOSPITALARIA. 2006. 21(Suppl 2): 72-84 *
RASTALL, R. A. et al., FEMS MICROBIOLOGY ECOLOGY. 2005. 52(2): 145-152 *
REID, G. APPLIED AND ENVIRONMENTAL MICROBIOLOGY. 1999. 65(9): 3763-3766 *
SANDERS, M.E. and KLAENHAMMER, T.R. JOURNAL OF DAIRY SCIENCE. 2001. 84(2): 319-331 *
SARAN S., et al., NUTRITION. 2002. 18(5): 393-396 *
SHINOHARA, M. et al., JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2002. 109(1): S76-S77 *
TEJADA-SIMON, M .V. et al., JOURNAL OF DAIRY SCIENCE. 1999. 82(4): 649-660 *
VIVATVAKIN, BOOSBA and KOWITDAMRONG, EKASIT. Journal of the Medical Association of Thailand. 2006. 89(suppl. 3): S126-33 *

Also Published As

Publication number Publication date
KR20140002069A (ko) 2014-01-07
DK2068899T3 (da) 2015-09-28
JP2010505824A (ja) 2010-02-25
PL2839836T3 (pl) 2018-02-28
KR101485200B1 (ko) 2015-01-26
CN101528244A (zh) 2009-09-09
US20140356329A1 (en) 2014-12-04
JP2014058558A (ja) 2014-04-03
PL2839836T5 (pl) 2025-11-17
DK2839836T4 (da) 2024-08-26
MX2009003260A (es) 2009-05-11
WO2008042101A3 (en) 2009-04-09
US20230256037A1 (en) 2023-08-17
FI2839836T4 (fi) 2024-08-26
DK2839836T3 (en) 2017-12-04
EP2068899A2 (en) 2009-06-17
AU2007302715A1 (en) 2008-04-10
EP2839836B2 (en) 2024-06-26
EP2839836B1 (en) 2017-08-30
US20100040579A1 (en) 2010-02-18
CN101528244B (zh) 2012-01-11
JP5896589B2 (ja) 2016-03-30
BRPI0719787A2 (pt) 2014-11-25
PL2068899T3 (pl) 2015-12-31
US20180000875A1 (en) 2018-01-04
US20200316145A1 (en) 2020-10-08
ES2650375T3 (es) 2018-01-18
KR101474188B1 (ko) 2014-12-17
EP2839836A1 (en) 2015-02-25
ES2547480T3 (es) 2015-10-06
KR20090063222A (ko) 2009-06-17
JP2016128478A (ja) 2016-07-14
WO2008042101A2 (en) 2008-04-10
EP2068899B1 (en) 2015-07-01
ES2650375T5 (en) 2025-02-03

Similar Documents

Publication Publication Date Title
US20230256037A1 (en) Probiotics for use in reducing the incidence and duration of illness
Saavedra et al. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety
Guillemard et al. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial
Lenoir-Wijnkoop et al. Probiotic and prebiotic influence beyond the intestinal tract
MXPA06014555A (es) Uso de una cantidad terapeuticamente efectiva de bb12 y lgg en la preparacion de un medicamento para prevenir o tratar infecciones respiratorias y otitis media aguda en lactantes.
EP2209527B1 (en) Pharmaceutical compositions comprising L. acidophilus and Bifidobacterium lactis for use in the treatment of functional bowel disorder
CN101076346B (zh) 乳酸菌及其在预防腹泻中的应用
AU2013201783B2 (en) Probiotics for use in reducing the incidence and duration of illness
Hoosain et al. Swallowing and feeding of young children on high-flow oxygen therapy
Hojsak et al. Guidance on paediatric use of probiotics states that benefits are limited to several conditions and urges caution with specific vulnerable groups
Lehtoranta Probiotics and immune modulation: reducing risk for cold and flu
Kloster Smerud et al. Effect of a probiotic milk product on gastrointestinal and respiratory infections in children attending day-care
Maldonado Lozano et al. Evaluation of the safety, tolerance and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomized controlled trial
US20160354419A9 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
Varshney et al. Cultural tourism: Challenges and opportunities (A conceptual paper-sultanate of Oman)
Mittal EFFECT OF PROBIOTICS ON TEETHING PROBLEMS IN INFANTS/TODDLERS
AndreyProdeus Fermented milk consumption and common infections in children attending day-care centers. A randomized trial
Udani et al. Probiotics for the Treatment of Helicobacter pylori
Desland et al. Commonly Asked Questions about Probiotics and the Potential Benefits for Your Health: MB005/MB005, 12/2011
HK1111883B (en) Use of a composition for preventing or treating respiratory infections and acute otitis media in infants

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: INTERNATIONAL N&H DENMARK APS

Free format text: FORMER NAME(S): DUPONT NUTRITION BIOSCIENCES APS